Robert Perrillo

On‐treatment prediction of sustained response to peginterferon alfa‐2a for HB eAg‐negative chronic hepatitis B patients

Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B

Management of hepatitis B

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

The Treatment of Chronic Viral Hepatitis

Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir

Review article: hepatitis B and liver transplantation

Mechanisms of type-I- and type-II-interferon-mediated signalling

Hepatitis B Virus Infection — Natural History and Clinical Consequences

Interactions Between Human Immunodeficiency Virus–1, Hepatitis Delta Virus and Hepatitis B Virus Infections in 260 Chronic Carriers of Hepatitis B Virus

American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

Virologic response and resistance to adefovir in patients with chronic hepatitis B

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

Comparison of Adefovir and Tenofovir in the Treatment of Lamivudine–Resistant Hepatitis B Virus Infection

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

Autoimmune liver disease: overlap and outliers

Small-Vessel Vasculitis

A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B

Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation

A robust cell culture system supporting the complete life cycle of hepatitis B virus

Transfusion Strategies for Acute Upper Gastrointestinal Bleeding

Hepatitis B and Hepatitis C Viruses in Liver Transplantation

Molecular diagnosis of viral hepatitis

Hepatitis B Virus Infection

Management of hepatitis B: 2000—Summary of a workshop

Long–Term Histologic and Virologic Outcomes of Acute Self–Limited Hepatitis B

Influence of Human Immunodeficiency Virus Infection on Chronic Hepatitis B in Homosexual Men

Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update*

Mesenchymal stem cells in health and disease

Diagnosis and Management of Autoimmune Hepatitis

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Efficacy of entecavir treatment for lamivudine‐resistant hepatitis B over 3 years: Histological improvement or entecavir resistance?

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

Hepatitis B virus infection

Rescue therapy for lamivudine‐resistant chronic hepatitis B: Comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add‐on lamivudine combination therapy

Chronic hepatitis B

Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-α therapy

American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B

A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

Is Hepatitis B Immunoglobulin Necessary in Prophylaxis of Hepatitis B Recurrence after Liver Transplantation? A Meta-Analysis

Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients

Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease

The RNA Sensor RIG-I Dually Functions as an Innate Sensor and Direct Antiviral Factor for Hepatitis B Virus

Liver grafts from anti-hepatitis B core positive donors: A systematic review

Treatment of chronic hepatitis B

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

Management of Hepatocellular Carcinoma *

Long-term follow-up of chronic hepatitis B patients treated with interferon alfa

Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination

Viral hepatitis B

High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects

Management of treatment failure in chronic hepatitis B

Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

Priming of hepatitis C virus-specific cytotoxic t lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA

Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level

Chronic hepatitis B

Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B

Chronic hepatitis B: Update 2009 #

Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B

De novo hepatitis B after liver transplantation from hepatitis B core antibody—Positive donors in an area with high prevalence of anti-HBc positivity in the donor population

Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy†

Optimal management of hepatitis B virus infection – EASL Special Conference

Expression of activation-induced cytidine deaminase in human hepatocytes via NF-κB signaling

Thymosin α₁ treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double‐blind and placebo‐controlled study

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy

Then and now: The progress in hepatitis B treatment over the past 20 years

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: A viral dynamics study

Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines

Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database

Novel Cd4+ and Cd8+ T–Cell Determinants Within the Ns3 Protein in Subjects With Spontaneously Resolved Hcv Infection

Efficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Bb

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus

Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation

Interferon therapy in chronic hepatitis C virus infection

Long–Term Follow–Up of Interferon Alfa Treatment in Chinese Patients With Chronic Hepatitis B Infection: the Effect on Hepatitis B E Antigen Seroconversion and the Development of Cirrhosis–Related Complications

Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide

Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B

Occult hepatitis B

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

Natural history of chronic HBV carriers in northern Italy: Morbidity and mortality after 30 years

Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)

Infection in Solid-Organ Transplant Recipients

Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

Antiretroviral Treatment of Adult HIV Infection

Evolution of Hepatitis B Virus Polymerase Gene Mutations in Hepatitis B E Antigen-Negative Patients Receiving Lamivudine Therapy

Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders

Hepatocellular Carcinoma

Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results

Early Switch From Intravenous to Oral Antibiotics in Hospitalized Patients With Bacteremic Community-Acquired Streptococcus pneumoniae Pneumonia

Clinical Aspects of the Interactions Between Human Immunodeficiency Virus and the Hepatotropic Viruses

Parvovirus B19

Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy

Adefovir Dipivoxil for Wait-Listed and Post–Liver Transplantation Patients with Lamivudine-Resistant Hepatitis B

Stromal-cell regulation of dendritic-cell differentiation and function

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

Prevalence, Patterns, and Course of Past Hepatitis B Virus Infection in Intravenous Drug Users With Hiv-1 Infection

Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B

A Multicenter United States—Canadian Trial to Assess Lamivudine Monotherapy Before and After Liver Transplantation for Chronic Hepatitis B

MIXED CRYOGLOBULINEMIA SECONDARY TO HEPATITIS C VIRUS INFECTION

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.

Prevalence of Parvovirus B19 in Liver Tissue: No Association with Fulminant Hepatitis or Hepatitis‐Associated Aplastic Anemia

HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma

Chronic Hepatitis B: Current Testing Strategies

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy

Long-term therapy of chronic hepatitis B with lamivudine

Hepatocellular Carcinoma

Water‐compatible molecularly imprinted polymer as a sorbent for the selective extraction and purification of adefovir from human serum and urine

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection

Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections

Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study

Variable Patterns of Programmed Death-1 Expression on Fully Functional Memory T Cells after Spontaneous Resolution of Hepatitis C Virus Infection

Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium

Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster

Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients

Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus

A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-α2b and Lamivudine with Lamivudine Alone

Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding

Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C

Glycobiology:  Toward Understanding the Function of Sugars

Progressive engineering of a homing endonuclease genome editing reagent for the murine X-linked immunodeficiency locus

A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis B

Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective

Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules

Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis

Anti‐viral therapy for prevention of perinatalHBVtransmission: extending therapy beyond birth does not protect against post‐partum flare

Meta‐analysis: oral anti‐viral agents in adults with decompensated hepatitis B virus cirrhosis

Review of solid-organ transplantation in HIV-infected patients

Fibrosis — A Common Pathway to Organ Injury and Failure

EASL Recommendations on Treatment of Hepatitis C 2018

EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure

Close Monitoring of Hepatitis B Surface Antigen Levels Helps Classify Flares During Peginterferon Therapy and Predicts Treatment Response

Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

RNA editing of hepatitis B virus transcripts by activation-induced cytidine deaminase

Pathogenic role of hepatitis B virus in hepatitis B surface antigen—negative decompensated cirrhosis

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

Targeted DNA Mutagenesis for the Cure of Chronic Viral Infections

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient

Fitness and infectivity of drug-resistant and cross-resistant HBV mutants: why and how is it studied?

Cutting Edge: Chronic Inflammatory Liver Disease in Mice Expressing a CD28-Specific Ligand

Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus

Comparison of Qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and Quantitative (COBAS AMPLICOR HCV Monitor 2.0 versus VERSANT HCV RNA 3.0) Assays for Hepatitis C Virus (HCV) RNA Detection and Quantification: Impact on Diagnosis and Treatment of HCV Infections

Interferon-α for HBeAg-positive chronic hepatitis B

Prevention of Hepatitis B Recurrence after Liver Transplantation

Treatment of Chronic Viral Hepatitis

Lack of Phenotypic and Functional Impairment in Dendritic Cells from Chimpanzees Chronically Infected with Hepatitis C Virus

Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects.

Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin.

Molecular imprinting: perspectives and applications

In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to (−)-β-d-2,6-Diaminopurine Dioxolane and 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyluracil

Immunosuppression in Patients with Chronic Hepatitis B

Selective Outpatient Management of Upper Gastrointestinal Bleeding in The Elderly

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

Prevalence of Herpesviridae and Hepatitis B Virus Dna in the Liver of Patients With Non–A, Non–B Fulminant Hepatic Failure

Hepatitis B: Reflections on the current approach to antiviral therapy

Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen

Treatment of Chronic Hepatitis B with Interferon: Experience in Western Countries

Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen–positive liver donation: A survey of North American, European, and Asian-Pacific transplant programs

Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy

Relationship between histology, aminotransferase levels, and viral replication in chronic hepatitis B

Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management

Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B

Multicenter Study of Lamivudine Therapy for Hepatitis B After Liver Transplantation

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

Benefits and risks of interferon therapy for hepatitis B #

Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection

Hepatitis C RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

A Pilot Study of Extended Duration Peginterferon Alfa-2a for Patients With Hepatitis B e Antigen-Negative Chronic Hepatitis B

Monitoring of antiviral therapy with quantitative evaluation of hbeag: A comparison with HBV DNA testing

Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies.

A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipovoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): Week 52 analysis

Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment

Multicenter studies of Lamivudine for the treatment and prevention of hepatitis B after liver transplantation.

Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature

Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis be-antigen (HBeAg) seroconversion

438 Continued safety and efficacy of adding adefovir dipivoxil (ADV) to ongoing lamivudine (LAM) therapy in compensated chronic hepatitis B (CHB) patients with YMDD variant HBV: 2 year results